Trial Profile
The efficacy of SGLT2 inhibitor switching from thiazolidine about body weight and metabolic-related factors in type 2 diabetes patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Dec 2019 Results assessing SGLT2 inhibitor with thiazolidine for their impact on nonalcoholic fatty liver disease presented at the 2019 Congress of the International Diabetes Federation
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 Oct 2017 Status changed from not yet recruiting to active, no longer recruiting.